Pair page
BPC-157 with GHRP-6
Mechanism-tag overlap and published literature for BPC-157 and GHRP-6, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
cytoprotectiontissue-repair
ghrelin-receptor-agonistgrowth-hormone-secretagogue
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying BPC-157 and GHRP-6 have published these mechanism-level observations. Not a co-administration recommendation.
For tissue-repair-plus-GH protocols. BPC-157 local repair signaling complements the systemic GH / IGF-1 elevation from GHRP-6 + GHRH. Common in injury recovery contexts.
Quick facts
BPC-157
GHRP-6
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2025 | BPC-157 | Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID: 40756949. (544 articles screened, 36 studies included — the single most comprehensive systematic revie… PMID 40756949 | systematic review |
| — | BPC-157 | ClinicalTrials.gov. Study of PL 14736 in Subjects With Ulcerative Colitis. NCT05765058. | human trial |
| 2025 | BPC-157 | Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. PMID: 40131143. PMID 40131143 | human pilot |
| 2024 | BPC-157 | Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. | human pilot |
| 2020 | BPC-157 | Xu C, Sun L, Ren F, Huang P, Tian Z, Cui J, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. (Independent safety study in mice, rats, rabbits, and dogs — no LD1 identifie… | preclinical, in vivo |
| 2006 | BPC-157 | Krivic A, Majerovic M, Jelic I, Seiwerth S, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-989. PMID: 16583442. PMID 16583442 | preclinical, in vivo |
| 2003 | BPC-157 | Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. PMID: 14554208. PMID 14554208 | preclinical, in vivo |
| 2025 | BPC-157 | McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMID: 40789979. PMID 40789979 | review |
| 2025 | BPC-157 | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025. | regulatory / registry |
| — | BPC-157 | USADA. BPC-157: Experimental Peptide Creates Risk for Athletes. U.S. Anti-Doping Agency. usada.org. | regulatory / registry |
| 2025 | BPC-157 | Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. PMID: 40005999. PMID 40005999 | research article |
| 2022 | BPC-157 | Vukojevic J, Milavic M, Perovic D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487. PMID: 34380875. PMID 34380875 | research article |
| 2013 | GHRP-6 | Cabrales A, Gil J, Fernández E, Valenzuela C, Hernández F, García I, Hernández A, Besada V, Reyes O, Padrón G, Berlanga J, Guillén G, González LJ. Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. Eur J Pharm Sci. 2013;48(1-2):… PMID 23159700 | human study |
| 2001 | GHRP-6 | Hataya Y, Akamizu T, Takaya K, et al. A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans. J Clin Endocrinol Metab. 2001;86(9):4552. PMID: 11549709. PMID 11549709 | human study |
| 2001 | GHRP-6 | Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab. 2001;86(3):1169-1174. PMID: 1… PMID 11238504 | human study |
| 1998 | GHRP-6 | Pandya N, DeMott-Friberg R, Bowers CY, Barkan AL, Jaffe CA. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. J Clin Endocrinol Metab. 1998;83(4):1186-1189. PMID: 9543138. (GHRH-GHRP synergy in humans.) PMID 9543138 | human study |
| 2013 | GHRP-6 | Cabrales A, Berlanga J, et al. Cardiotropic effect of GHRP-6: in vivo characterization by echocardiography. Biotecnología Aplicada. 2013;30(4):285-289. (Inotropic effect characterization.) | preclinical, in vivo |
| 2005 | GHRP-6 | Depoortere I, De Winter B, Thijs T, De Man J, Pelckmans P, Peeters T. Comparison of the gastroprokinetic effects of ghrelin, GHRP-6 and motilin in rats in vivo and in vitro. Eur J Pharmacol. 2005;515(1-3):160-168. PMID: 15890335. (Gastric prokinetic mechanism.) PMID 15890335 | preclinical, in vivo |
| 2005 | GHRP-6 | Granado M, Priego T, Martín AI, Villanúa MA, López-Calderón A. Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am J Physiol Endocrinol Metab. 2005;288(3):E486-492. PMID: 15507534. (GHRP family anti-inflammatory mecha… PMID 15507534 | preclinical, in vivo |
| 1984 | GHRP-6 | Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545. PMID: 6142782. (Foundational GHRP-6 discovery paper.) PMID 6142782 | preclinical, in vivo |
| 2002 | GHRP-6 | Bodart V, Febbraio M, Demers A, McNicoll N, Pohankova P, Perreault A, Sejlitz T, Escher E, Silverstein RL, Lamontagne D, Ong H. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res. 2002;90(8):844-849. PMID: 11988484. (CD36 cardiopr… PMID 11988484 | mechanism / discovery |
| 2001 | GHRP-6 | Bowers CY. Unnatural growth hormone-releasing peptide begets natural ghrelin. J Clin Endocrinol Metab. 2001;86(4):1464-9. PMID: 11297568. (Bowers' personal review of the discovery arc from synthetic to natural ligand.) PMID 11297568 | mechanism / discovery |
| 1999 | GHRP-6 | Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. PMID: 10604470. (Discovery of the natural endogenous ligand of GHS-R1a.) PMID 10604470 | mechanism / discovery |
| 1996 | GHRP-6 | Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. PMID: 8688086. (Cloning of GHS-R1a using GHRP-6 as the radioligand.) PMID 8688086 | mechanism / discovery |
Related pair pages
More research context
Frequently asked
Have BPC-157 and GHRP-6 been studied together?
Researchers have published mechanistic-level co-administration discussion of BPC-157 and GHRP-6. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do BPC-157 and GHRP-6 share?
BPC-157 and GHRP-6 do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of BPC-157 and GHRP-6?
BPC-157: Category 2 (reclassification pending). GHRP-6: Investigational (Category 2 bulk). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on BPC-157 and GHRP-6?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the BPC-157 profile and the GHRP-6 profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026